In February love is in the air, and we want you to know that you are always in our hearts and minds. For all the Valentine’s Day celebrations at school, be sure to remind your child’s teachers of any food allergies they have. Visit SnackSafely.com for Dave Bloom's complete and accurate list of allergen-free treats.
Aimmune Therapeutics, the company that has developed and tested Palforzia, states that the medication is intended to treat children ages 4 to 17 that have been diagnosed with a peanut allergy. It’s estimated that more than 1 million children (2.2%) in the United States have peanut allergies. Until now, parents who wanted keep their kids safe have had very few options.
The need for a treatment for peanut allergies becomes more apparent when a recent study showed that those living with an allergy to peanuts have almost double the annual healthcare costs for patients who didn’t have a peanut allergy. Out of 42,000 people studied, 36% of the peanut allergy patients had experienced anaphylaxis and 33% had visited an emergency department, compared to 20% of those without a peanut allergy.
-The yearly “all-cause” healthcare costs for patients who had a peanut allergy diagnostic code was $6,400 a year. That was almost double the “all-cause” annual healthcare costs ($3,500) for patients who didn’t have the peanut allergy code.
-In a follow-up analysis of the next 12 months, 36% of the peanut allergy patients had a code in their records showing they’d been treated for an anaphylactic reaction.
-In the original analysis, 33% of the peanut allergy patients had visited an emergency department, compared to 20% without peanut allergy.
2020/02/06 -Pre-IND Meeting on AQST-108 Completed -FDA Confirmed AQST-108 To Be Reviewed Under 505(b)(2) -No Additional Clinical Studies Would Be Required Prior to Opening Proposed IND -Pivotal Pharmacokinetic (PK) Clinical Trials Planned To Be Initiated Before Year End 2020
If defibrillators are required on every airliner, why not an epinephrine auto-injector? Despite resistance from the airline industry, two U.S. Senators and a Representative recently urged the Federal Aviation Administration (FAA) to require that U.S.-based commercial airlines include EAI devices in their onboard emergency medical kits (EMKs). Rep. Khanna of California has been particularly supportive in leading the campaign for greater funding into allergy research and treatment options. She helped secure an increase of $362 million in funding for the National Institute of Allergy and Infectious Disease (NIAID) with a directive to invest in food allergy research, and an additional $10 million for the Peer-Reviewed Medical Research Program (PRMRP) under the Department of Defense.
“This Is A Simple Step That Will Undoubtedly Save Countless Lives.”